በ MRD እና በ CAR T-cell ሕክምና መካከል ያለውን ግንኙነት መረዳት
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
በኒውሮሎጂካል መዛባቶች ውስጥ የሜዲካል ሴል ሕክምና
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
ወላጅ አልባ መድሀኒት ስያሜ በኤፍዲኤ የተሰጠው ለ CART T-cell Therapy A2B530 የኮሎሬክታል ካንሰርን ለማከም ነው።
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Iovance's Amtagvi በUSFDA የጸደቀው ለጠንካራ እጢ የመጀመሪያ ቲ-ሴል ሕክምና ነው።
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
Amivantamab-vmjw በዩኤስኤፍዲኤ የፀደቀው ለEGFR exon 20 የማስገባት-የተቀየረ አነስተኛ ሕዋስ የሳንባ ካንሰር ምልክቶች
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
ኦሲሜርቲኒብ ከኬሞቴራፒ ጋር በ EGFR ለተቀየረ አነስተኛ ሕዋስ የሳንባ ካንሰር በUSFDA ጸደቀ።
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Lifileucel ላልተመረቀ ወይም ለሜታስታቲክ ሜላኖማ በUSFDA ጸድቋል
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
ቴፖቲኒብ በUSFDA ተፈቅዶለታል ለሜታስታቲክ አነስተኛ ሕዋስ የሳንባ ካንሰር
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
አይሪኖቴካን ሊፖሶም በዩኤስኤፍዲኤ የተፈቀደው ለሜታስታቲክ የጣፊያ adenocarcinoma የመጀመሪያ መስመር ሕክምና ነው።
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
Erdafitinib በUSFDA ለአካባቢው የላቀ ወይም ለሜታስታቲክ urothelial ካርስኖማ ጸድቋል
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..